Cabozantinib Plus Atezolizumab Delays Progression in mCRPC

(MedPage Today) -- SAN FRANCISCO -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news